| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 114 | 2024 | 16053 | 3.820 |
Why?
|
| Receptor, ErbB-2 | 31 | 2024 | 2617 | 2.100 |
Why?
|
| Diphosphonates | 12 | 2007 | 266 | 1.670 |
Why?
|
| Complementary Therapies | 6 | 2015 | 132 | 1.510 |
Why?
|
| Bone Neoplasms | 19 | 2014 | 2652 | 1.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2024 | 16270 | 1.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2017 | 203 | 1.080 |
Why?
|
| Trastuzumab | 20 | 2023 | 718 | 0.940 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2013 | 347 | 0.910 |
Why?
|
| Antibodies, Monoclonal, Humanized | 18 | 2024 | 3363 | 0.840 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 132 | 0.780 |
Why?
|
| Drugs, Chinese Herbal | 4 | 2007 | 61 | 0.740 |
Why?
|
| Purines | 2 | 2017 | 275 | 0.650 |
Why?
|
| Female | 125 | 2024 | 147292 | 0.640 |
Why?
|
| Pain | 16 | 2011 | 1694 | 0.640 |
Why?
|
| Aminopyridines | 2 | 2017 | 219 | 0.630 |
Why?
|
| Antineoplastic Agents | 24 | 2016 | 14506 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 6 | 2020 | 2379 | 0.620 |
Why?
|
| Clinical Protocols | 1 | 2020 | 471 | 0.610 |
Why?
|
| Neoplasms | 16 | 2018 | 15710 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 14 | 2021 | 4452 | 0.570 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2011 | 2734 | 0.560 |
Why?
|
| Phytotherapy | 3 | 2010 | 116 | 0.550 |
Why?
|
| Humans | 145 | 2024 | 270843 | 0.550 |
Why?
|
| Neoadjuvant Therapy | 13 | 2024 | 5113 | 0.540 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 131 | 0.540 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 556 | 0.540 |
Why?
|
| Receptors, Estrogen | 10 | 2023 | 2122 | 0.530 |
Why?
|
| Carcinoma, Lobular | 3 | 2024 | 620 | 0.490 |
Why?
|
| Quality Improvement | 1 | 2022 | 925 | 0.490 |
Why?
|
| Deoxycytidine | 3 | 2007 | 1374 | 0.470 |
Why?
|
| Tamoxifen | 9 | 2020 | 884 | 0.460 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 279 | 0.450 |
Why?
|
| Biomarkers, Tumor | 15 | 2024 | 10627 | 0.450 |
Why?
|
| Pyridines | 1 | 2020 | 1291 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2018 | 9067 | 0.430 |
Why?
|
| Bone Diseases | 1 | 2014 | 140 | 0.430 |
Why?
|
| Analgesics | 8 | 2011 | 400 | 0.400 |
Why?
|
| Breast | 3 | 2024 | 1361 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2024 | 1295 | 0.390 |
Why?
|
| Piperazines | 1 | 2020 | 2131 | 0.390 |
Why?
|
| Clinical Trials as Topic | 11 | 2015 | 3836 | 0.380 |
Why?
|
| Treatment Outcome | 33 | 2020 | 34238 | 0.380 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 808 | 0.370 |
Why?
|
| Radiology | 2 | 2015 | 451 | 0.370 |
Why?
|
| Mammography | 3 | 2015 | 1030 | 0.370 |
Why?
|
| Plant Extracts | 3 | 2010 | 226 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 10257 | 0.360 |
Why?
|
| Nitriles | 4 | 2024 | 938 | 0.360 |
Why?
|
| Patient Compliance | 4 | 2012 | 685 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2018 | 424 | 0.350 |
Why?
|
| Bridged-Ring Compounds | 3 | 2020 | 183 | 0.350 |
Why?
|
| Biological Therapy | 2 | 2012 | 57 | 0.340 |
Why?
|
| Middle Aged | 66 | 2024 | 89535 | 0.340 |
Why?
|
| Drug Approval | 1 | 2010 | 185 | 0.340 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 318 | 0.330 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 342 | 0.330 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 395 | 0.330 |
Why?
|
| Neoplasm Metastasis | 16 | 2024 | 5239 | 0.330 |
Why?
|
| Everolimus | 3 | 2023 | 419 | 0.310 |
Why?
|
| Taxoids | 5 | 2020 | 994 | 0.310 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 1261 | 0.310 |
Why?
|
| Bone Density Conservation Agents | 2 | 2007 | 204 | 0.310 |
Why?
|
| Disease-Free Survival | 16 | 2023 | 10093 | 0.310 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2016 | 505 | 0.310 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 292 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4895 | 0.310 |
Why?
|
| Administration, Oral | 10 | 2006 | 1583 | 0.300 |
Why?
|
| Aromatase Inhibitors | 2 | 2013 | 312 | 0.300 |
Why?
|
| Communication | 2 | 2014 | 908 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2021 | 848 | 0.300 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 1228 | 0.290 |
Why?
|
| Aged | 48 | 2024 | 72902 | 0.280 |
Why?
|
| Patient Selection | 6 | 2015 | 2117 | 0.270 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4925 | 0.270 |
Why?
|
| Tumor Burden | 5 | 2021 | 2019 | 0.260 |
Why?
|
| Genetic Therapy | 2 | 2004 | 1630 | 0.260 |
Why?
|
| Paclitaxel | 6 | 2024 | 2056 | 0.260 |
Why?
|
| Oncogenes | 2 | 2004 | 677 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2002 | 1329 | 0.260 |
Why?
|
| Refusal to Participate | 1 | 2005 | 2 | 0.260 |
Why?
|
| Receptors, Androgen | 2 | 2024 | 893 | 0.260 |
Why?
|
| Carcinoma in Situ | 2 | 2023 | 496 | 0.250 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 1101 | 0.250 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 233 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 1571 | 0.230 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1937 | 0.230 |
Why?
|
| Bevacizumab | 3 | 2016 | 947 | 0.230 |
Why?
|
| Adult | 48 | 2024 | 80709 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2004 | 238 | 0.220 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 105 | 0.220 |
Why?
|
| Estrogens | 4 | 2013 | 758 | 0.220 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2023 | 17 | 0.220 |
Why?
|
| Fluorouracil | 2 | 2007 | 1967 | 0.220 |
Why?
|
| Survival Analysis | 10 | 2023 | 9324 | 0.220 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2023 | 77 | 0.220 |
Why?
|
| Postmenopause | 3 | 2021 | 379 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2007 | 667 | 0.220 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2002 | 31 | 0.220 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 47 | 0.210 |
Why?
|
| Dietary Supplements | 2 | 2007 | 585 | 0.210 |
Why?
|
| Drug Design | 1 | 2005 | 383 | 0.210 |
Why?
|
| Patient Participation | 2 | 2012 | 478 | 0.200 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 2 | 2011 | 28 | 0.200 |
Why?
|
| Karnofsky Performance Status | 3 | 2018 | 176 | 0.200 |
Why?
|
| Receptors, Progesterone | 5 | 2020 | 1415 | 0.200 |
Why?
|
| Triazoles | 3 | 2016 | 630 | 0.200 |
Why?
|
| Proportional Hazards Models | 8 | 2020 | 5116 | 0.200 |
Why?
|
| Attitude to Health | 1 | 2005 | 467 | 0.200 |
Why?
|
| Technology | 1 | 2022 | 104 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2023 | 5295 | 0.190 |
Why?
|
| Receptors, CXCR4 | 1 | 2023 | 273 | 0.190 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 14855 | 0.190 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 219 | 0.190 |
Why?
|
| Mitosis | 1 | 2023 | 623 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 683 | 0.180 |
Why?
|
| Gene Amplification | 5 | 2018 | 745 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 707 | 0.180 |
Why?
|
| Gangliosides | 1 | 2021 | 110 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 2210 | 0.180 |
Why?
|
| Patient Education as Topic | 5 | 2005 | 766 | 0.180 |
Why?
|
| Research Design | 5 | 2020 | 1598 | 0.170 |
Why?
|
| Self Care | 4 | 2007 | 231 | 0.170 |
Why?
|
| Mastectomy, Segmental | 3 | 2020 | 1042 | 0.170 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 30813 | 0.170 |
Why?
|
| Cell Cycle | 3 | 2017 | 2117 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 162 | 0.170 |
Why?
|
| Heart Diseases | 3 | 2004 | 756 | 0.170 |
Why?
|
| Estradiol | 2 | 2013 | 761 | 0.170 |
Why?
|
| Prognosis | 11 | 2023 | 22249 | 0.160 |
Why?
|
| Neutropenia | 1 | 2023 | 987 | 0.160 |
Why?
|
| Pain Management | 4 | 2007 | 703 | 0.160 |
Why?
|
| Benzamides | 1 | 2024 | 1873 | 0.160 |
Why?
|
| Mammaplasty | 3 | 2024 | 791 | 0.160 |
Why?
|
| Internet | 2 | 2014 | 730 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2015 | 6269 | 0.160 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2018 | 152 | 0.160 |
Why?
|
| Signal Transduction | 7 | 2021 | 12151 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 881 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 612 | 0.150 |
Why?
|
| Research | 2 | 2015 | 436 | 0.150 |
Why?
|
| Apoptosis | 4 | 2023 | 7759 | 0.150 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 4386 | 0.150 |
Why?
|
| Cell Proliferation | 6 | 2018 | 7303 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2003 | 829 | 0.140 |
Why?
|
| Mastectomy | 4 | 2024 | 1558 | 0.140 |
Why?
|
| Indazoles | 1 | 2018 | 302 | 0.140 |
Why?
|
| Genes, erbB-2 | 3 | 2004 | 232 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 523 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2017 | 109 | 0.140 |
Why?
|
| Biomarkers | 3 | 2019 | 5176 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 121 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2021 | 3960 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2495 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2017 | 302 | 0.130 |
Why?
|
| Metabolome | 1 | 2019 | 351 | 0.130 |
Why?
|
| Combined Modality Therapy | 8 | 2015 | 9010 | 0.130 |
Why?
|
| Infusions, Intravenous | 5 | 2006 | 1410 | 0.130 |
Why?
|
| Neoplasm Staging | 11 | 2019 | 13882 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 909 | 0.130 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 25 | 0.130 |
Why?
|
| Femoral Fractures | 1 | 2016 | 60 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 621 | 0.130 |
Why?
|
| Disease Progression | 10 | 2016 | 6891 | 0.130 |
Why?
|
| Pain, Intractable | 2 | 2011 | 171 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 1313 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2004 | 2329 | 0.130 |
Why?
|
| Placebos | 3 | 2005 | 448 | 0.130 |
Why?
|
| Cyclophosphamide | 6 | 2020 | 3144 | 0.120 |
Why?
|
| Morbidity | 3 | 2004 | 414 | 0.120 |
Why?
|
| Psychophysiology | 2 | 2007 | 14 | 0.120 |
Why?
|
| Capecitabine | 2 | 2024 | 390 | 0.120 |
Why?
|
| Bone Resorption | 3 | 2005 | 137 | 0.120 |
Why?
|
| Outpatients | 2 | 2011 | 475 | 0.120 |
Why?
|
| Doxorubicin | 6 | 2020 | 3059 | 0.120 |
Why?
|
| Resistance Training | 1 | 2014 | 43 | 0.110 |
Why?
|
| Maytansine | 1 | 2014 | 39 | 0.110 |
Why?
|
| Mutation | 3 | 2018 | 15642 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2015 | 308 | 0.110 |
Why?
|
| Receptors, Growth Factor | 1 | 1994 | 163 | 0.110 |
Why?
|
| Survivors | 3 | 2014 | 1030 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 124 | 0.110 |
Why?
|
| Carboplatin | 1 | 2016 | 844 | 0.110 |
Why?
|
| Growth Substances | 1 | 1994 | 308 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2016 | 438 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 4 | 2011 | 559 | 0.110 |
Why?
|
| Quinolines | 1 | 2016 | 396 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 361 | 0.110 |
Why?
|
| Premenopause | 2 | 2021 | 136 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2024 | 13310 | 0.110 |
Why?
|
| Androstadienes | 1 | 2013 | 171 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1470 | 0.110 |
Why?
|
| Dementia | 1 | 2018 | 489 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 65 | 0.100 |
Why?
|
| Receptors, Steroid | 3 | 2021 | 293 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 980 | 0.100 |
Why?
|
| Animals | 11 | 2024 | 61014 | 0.100 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 5242 | 0.100 |
Why?
|
| Ribonucleotide Reductases | 2 | 2002 | 51 | 0.100 |
Why?
|
| Sarcoma | 1 | 2023 | 1830 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2981 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2023 | 9487 | 0.100 |
Why?
|
| Decision Making | 2 | 2015 | 1344 | 0.100 |
Why?
|
| Perception | 1 | 2014 | 358 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 202 | 0.100 |
Why?
|
| Microtubules | 1 | 2012 | 267 | 0.100 |
Why?
|
| Mice | 7 | 2024 | 35331 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 640 | 0.100 |
Why?
|
| Scutellaria | 2 | 2010 | 6 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2004 | 3518 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7962 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 379 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2023 | 39512 | 0.090 |
Why?
|
| Biopsy | 2 | 2015 | 3490 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 637 | 0.090 |
Why?
|
| United States | 4 | 2015 | 16339 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2019 | 7170 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2013 | 763 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 1896 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2010 | 474 | 0.080 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 1988 | 16 | 0.080 |
Why?
|
| Sirolimus | 1 | 2013 | 834 | 0.080 |
Why?
|
| Heart Block | 1 | 1988 | 49 | 0.080 |
Why?
|
| alpha-Glucosidases | 1 | 1988 | 58 | 0.080 |
Why?
|
| Male | 19 | 2018 | 127630 | 0.080 |
Why?
|
| Quinazolines | 1 | 2013 | 934 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6245 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 5123 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 781 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 90 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2013 | 1800 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2015 | 1470 | 0.080 |
Why?
|
| Anthracyclines | 2 | 2011 | 332 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 647 | 0.070 |
Why?
|
| Safety | 3 | 2004 | 471 | 0.070 |
Why?
|
| Acupuncture | 1 | 2007 | 22 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2011 | 679 | 0.070 |
Why?
|
| Cell Movement | 4 | 2021 | 2499 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 199 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2018 | 4887 | 0.070 |
Why?
|
| Exercise | 1 | 2014 | 1220 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 547 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3609 | 0.070 |
Why?
|
| Nursing Methodology Research | 1 | 2005 | 17 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3074 | 0.060 |
Why?
|
| Mastectomy, Radical | 1 | 2004 | 41 | 0.060 |
Why?
|
| Neoplasm Grading | 3 | 2015 | 1808 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2004 | 93 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 2021 | 1016 | 0.060 |
Why?
|
| Medical Records | 2 | 2005 | 425 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2013 | 2055 | 0.060 |
Why?
|
| Pain Measurement | 5 | 2011 | 996 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2006 | 2662 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2005 | 251 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2021 | 1864 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 685 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2004 | 69 | 0.060 |
Why?
|
| Quality of Life | 6 | 2014 | 4721 | 0.060 |
Why?
|
| Pyroptosis | 1 | 2024 | 28 | 0.060 |
Why?
|
| Time Factors | 7 | 2015 | 13266 | 0.060 |
Why?
|
| Risk Factors | 6 | 2019 | 18267 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2004 | 108 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2012 | 5930 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2004 | 337 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2005 | 582 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 221 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4646 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 879 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 5511 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 619 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2003 | 117 | 0.050 |
Why?
|
| Soy Foods | 1 | 2002 | 15 | 0.050 |
Why?
|
| Oncology Nursing | 1 | 2002 | 51 | 0.050 |
Why?
|
| Myocardium | 1 | 1988 | 1335 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 7704 | 0.050 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 5031 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2005 | 627 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2024 | 375 | 0.050 |
Why?
|
| Comorbidity | 2 | 2019 | 2454 | 0.050 |
Why?
|
| Home Care Services | 1 | 2002 | 97 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2016 | 1057 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2005 | 449 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 681 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6196 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3931 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2260 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 1568 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 568 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 446 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 712 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2003 | 643 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2001 | 54 | 0.050 |
Why?
|
| Water | 1 | 2002 | 376 | 0.050 |
Why?
|
| Transcriptome | 2 | 2023 | 1952 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 509 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 4062 | 0.040 |
Why?
|
| Acupuncture Therapy | 1 | 2001 | 93 | 0.040 |
Why?
|
| Cell Division | 2 | 2002 | 2556 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 948 | 0.040 |
Why?
|
| Caregivers | 2 | 2003 | 729 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2021 | 4343 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 505 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 727 | 0.040 |
Why?
|
| Incidence | 3 | 2016 | 5904 | 0.040 |
Why?
|
| Sex Factors | 1 | 2004 | 2217 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2019 | 2084 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1354 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 139 | 0.040 |
Why?
|
| Mexican Americans | 1 | 2020 | 328 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 1429 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 957 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4995 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 151 | 0.040 |
Why?
|
| Heart | 1 | 2004 | 1255 | 0.040 |
Why?
|
| California | 2 | 2012 | 221 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 5030 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2011 | 5362 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2001 | 653 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 1134 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 342 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4781 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5938 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 4462 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1348 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 546 | 0.030 |
Why?
|
| Heart Failure | 2 | 2013 | 2663 | 0.030 |
Why?
|
| Texas | 2 | 2017 | 6460 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2004 | 1367 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1994 | 600 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 931 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 487 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 3666 | 0.030 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1179 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2014 | 36 | 0.030 |
Why?
|
| Biosynthetic Pathways | 1 | 2014 | 48 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 1280 | 0.030 |
Why?
|
| Registries | 2 | 2014 | 2288 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2009 | 531 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 494 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 963 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 935 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2364 | 0.030 |
Why?
|
| Stress Fibers | 1 | 2013 | 15 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 394 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2014 | 125 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2020 | 1564 | 0.030 |
Why?
|
| Palliative Care | 2 | 2002 | 2130 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 155 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 836 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 66 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 169 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2009 | 695 | 0.030 |
Why?
|
| Racism | 1 | 2013 | 53 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 578 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 1716 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 2989 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 3062 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 7908 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 336 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2002 | 1426 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 1992 | 82 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2013 | 271 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2015 | 1182 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 248 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 121 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 587 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1992 | 144 | 0.020 |
Why?
|
| Physician's Role | 1 | 2014 | 246 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 2052 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2013 | 573 | 0.020 |
Why?
|
| Young Adult | 3 | 2015 | 22140 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 11817 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1992 | 131 | 0.020 |
Why?
|
| Cisplatin | 1 | 1998 | 2456 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 473 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2004 | 625 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 3955 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 1708 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1891 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2009 | 1444 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2005 | 1693 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1992 | 319 | 0.020 |
Why?
|
| Genes, myc | 1 | 1992 | 360 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 997 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 404 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 150 | 0.020 |
Why?
|
| Palpation | 1 | 2009 | 52 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 399 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1079 | 0.020 |
Why?
|
| Membranes | 1 | 1988 | 31 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2020 | 3033 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 3594 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 675 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 3621 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1513 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 611 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 835 | 0.020 |
Why?
|
| Phenotype | 2 | 2015 | 6404 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4544 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 178 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 797 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1559 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1233 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2319 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3294 | 0.020 |
Why?
|
| Muscles | 1 | 1988 | 423 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 304 | 0.020 |
Why?
|
| Ultrasonography, Mammary | 1 | 2009 | 383 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3522 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 109 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 1314 | 0.020 |
Why?
|
| Lysosomes | 1 | 1988 | 348 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 991 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1142 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 353 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1496 | 0.020 |
Why?
|
| Tape Recording | 1 | 2005 | 15 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3596 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5506 | 0.020 |
Why?
|
| Alleles | 1 | 1992 | 2488 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 200 | 0.020 |
Why?
|
| Affect | 1 | 2007 | 291 | 0.020 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 23 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 620 | 0.010 |
Why?
|
| International Cooperation | 1 | 2005 | 322 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 590 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2009 | 719 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2273 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4876 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 1615 | 0.010 |
Why?
|
| Toremifene | 1 | 2003 | 8 | 0.010 |
Why?
|
| Creatinine | 1 | 2006 | 552 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 844 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 1533 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 691 | 0.010 |
Why?
|
| Clinical Nursing Research | 1 | 2002 | 8 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1335 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 572 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2003 | 78 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2003 | 43 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 115 | 0.010 |
Why?
|
| DNA Repair | 1 | 2010 | 1908 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 110 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1992 | 2560 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2341 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2002 | 108 | 0.010 |
Why?
|
| Education, Nursing | 1 | 2002 | 19 | 0.010 |
Why?
|
| North Carolina | 1 | 2001 | 133 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1395 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 7429 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 1859 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 5716 | 0.010 |
Why?
|
| Piperidines | 1 | 2006 | 1067 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 1497 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 15198 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 1701 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1642 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 1060 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 3238 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3399 | 0.010 |
Why?
|
| Health Behavior | 1 | 2002 | 626 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1999 | 769 | 0.010 |
Why?
|
| Fever | 1 | 2001 | 512 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 5132 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 2200 | 0.010 |
Why?
|
| Adolescent | 2 | 2006 | 32336 | 0.010 |
Why?
|
| General Surgery | 1 | 2000 | 345 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2000 | 2868 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2001 | 2095 | 0.010 |
Why?
|